About seven months after closing its Phase III study with apricitabine (ATC) for HIV ahead of schedule, Avexa Ltd., quit development of the nucleoside reverse transcriptase inhibitor entirely, saying the final would-be partner has declined to submit a term sheet and staff is being reduced as the company considers options. (BioWorld Today) Read More